Stoke Therapeutics Inc represents values of innovation, collaboration, and commitment to patients. The company's corporate philosophy revolves around developing transformative treatments for severe genetic diseases. Stoke is dedicated to harnessing the power of RNA biology to address the underlying cause of such diseases. By prioritizing scientific advancement and partnerships, Stoke Therapeutics Inc aims to make a positive impact on patients' lives. The company strives to excel in translating cutting-edge research into therapeutic breakthroughs, offering hope and delivering long-term value for patients, their families, and the healthcare community.

Stoke Therapeutics Inc is primarily present in the United States.

Stoke Therapeutics Inc has achieved several significant milestones. The company successfully completed its initial public offering in June 2019, raising approximately $142 million in net proceeds. In January 2020, Stoke Therapeutics received the FDA's rare pediatric disease designation for its lead product candidate, STK-001, which aims to treat Dravet syndrome, a severe form of epilepsy. Furthermore, the company initiated a Phase 1/2a clinical trial of STK-001 in October 2020. Stoke Therapeutics continues to make progress in advancing its pipeline and developing innovative therapies for genetic diseases.

Stoke Therapeutics Inc is a biotechnology company founded in 2018, based in Bedford, Massachusetts. Focused on addressing the underlying causes of severe genetic diseases, Stoke Therapeutics utilizes its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform. This platform enables the development of antisense oligonucleotide (ASO) therapies to increase protein levels and restore gene expression. By targeting RNA instead of DNA, Stoke Therapeutics aims to treat a range of genetic disorders, including genetic epilepsies, genetic conditions affecting the central nervous system, and other rare diseases. Their innovative approach holds promise for patients with limited treatment options, making Stoke Therapeutics a key player in the biotech industry.

The main competitors of Stoke Therapeutics Inc in the market include companies such as Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Akcea Therapeutics.

Stoke Therapeutics Inc is primarily active in the biotechnology industry.

The business model of Stoke Therapeutics Inc revolves around developing innovative RNA-targeted therapeutics to treat severe genetic diseases. By focusing on addressing the underlying causes of diseases, Stoke Therapeutics aims to provide long-term solutions for patients. Its proprietary technology platform, Targeted Augmentation of Nuclear Gene Output (TANGO), enables the modulation of gene expression levels to restore the production of functional proteins. Stoke Therapeutics collaborates with industry partners and utilizes its expertise in RNA biology to advance potential therapies for a range of genetic disorders. Through its business model, the company aims to improve the lives of patients with severe genetic diseases through innovative and targeted treatments.

Το Stoke Therapeutics P/E είναι -5,28.

Το KUV της εταιρείας Stoke Therapeutics είναι 44,00.

Το AlleAktien Qualitätsscore για το Stoke Therapeutics είναι 3/10.

Ο κύκλος εργασιών του αναμενόμενη Stoke Therapeutics είναι 14,58 Εκ. USD.

Το αναμενόμενη Stoke Therapeutics κέρδος είναι -121,54 Εκ. USD.

Stoke Therapeutics Inc. is a biopharmaceutical company focused on developing technologies and therapies for the treatment of rare genetic diseases. Their business model is based on the application of a novel technology platform called Targeted Augmentation of Nuclear Gene Output (TANGO), which allows for the increase or decrease of gene expression. They aim to achieve therapeutic effects by specifically augmenting gene expression through their TANGO platform, which involves developing RNA molecules known as antisense oligonucleotides (ASOs) to modulate gene expression. Stoke Therapeutics has multiple products in various stages of development, with their most advanced candidate, STK-001, targeting the treatment of autosomal recessive spinobulbar muscular atrophy (SMA). They are also working on therapies for other rare diseases such as autosomal dominant optic atrophy (ADOA) and Dravet syndrome. Overall, Stoke Therapeutics focuses on developing RNA-based therapeutics for rare genetic diseases caused by loss-of-function mutations.

Η Stoke Therapeutics καταβάλλει μια διανομή της τάξεως των 0 USD διαμοιρασμένη σε δόσεις ετησίως.

Το μέρισμα δεν μπορεί να υπολογιστεί για το Stoke Therapeutics αυτή τη στιγμή ή η εταιρεία δεν διανέμει μέρισμα.

Ο αριθμός ISIN της Stoke Therapeutics είναι US86150R1077.

Το WKN της Stoke Therapeutics είναι A2PLTL.

Ο τίκερ της Stoke Therapeutics είναι STOK.

Κατά τους τελευταίους 12 μήνες η Stoke Therapeutics κατέβαλε μια μέρισμα ύψους . Αυτό αντιστοιχεί σε απόδοση μερίσματος περίπου . Για τους επόμενους 12 μήνες, η Stoke Therapeutics προβλέπεται να πληρώσει μέρισμα 0 USD.

Η απόδοση μερίσματος της Stoke Therapeutics ανέρχεται σήμερα στο .

Stoke Therapeutics πληρώνει τέταρτον διανεμητέου μισθό. Αυτή καταβάλλεται τους μήνες .

Η Stoke Therapeutics πλήρωσε κάθε χρόνο μέρισμα μέσα στα τελευταία 0 έτη.

Για τους επόμενους 12 μήνες αναμένονται μερίσματα σε ύψος των 0 USD. Αυτό αντιστοιχεί σε απόδοση μερίσματος 0 %.

Το Stoke Therapeutics ανατίθεται στον τομέα 'Υγεία'.

Για να λάβεις το τελευταίο μέρισμα των Stoke Therapeutics από την 16/7/2024 με τιμή 0 USD, έπρεπε να έχεις τη μετοχή στο χαρτοφυλάκιο σου πριν από την ημέρα Ex-Tag στις 16/7/2024.

Η τελευταία μερίσματος έγινε στις 16/7/2024.

Το έτος 2023, η Stoke Therapeutics διένειμε 0 USD ως μερίσματα.

Τα μερίσματα του Stoke Therapeutics καταβάλλονται σε USD.